Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

PSP produces first Y1-rating in UFS Faculty of Economic and Management Sciences
2015-12-14

Dr Andrew Cohen, a research fellow at the University of the Free State, recently received a distinguished National Research Foundation Y1-rating.
Photo: Sonia Small

The latest success story of the Vice-Chancellor’s Prestige Scholars Programme (PSP) is that the first National Research Foundation (NRF) Y1-rating was awarded recently to a scholar while teaching in the Faculty of Economic and Management Sciences at the University of the Free State (UFS).

Dr Andrew Cohen received this distinguished rating on 10 November 2015. It is awarded to a “young” (younger than 40) scholar five years or less post-PhD, whose curriculum vitae predicts, according to a panel of international and local reviewers, that he is poised to become a leader in his field. Dr Cohen is a research fellow at the UFS.

This rating is a reflection of Dr Cohen’s record over the past eight years, and the scholarly environment he was part of at the UFS under leadership of Prof Ian Phimister. Cohen is currently a research fellow in Prof Phimister’s International Studies Group.  He taught economic history in the Department of Economics until September 2015, when he joined the School of History at the University of Kent.

Dr Cohen’s professional trajectory is emblematic of the visionary approach of the UFS Prestige Scholars Programme (PSP): to support prestige scholars with advanced mentorship, and the creation of a college of peers in order to nurture intellectual breadth and depth to generate knowledge over disciplines.

The PSP was initiated by Prof Jonathan Jansen, Vice-Chancellor and Rector of the UFS in 2011.

“Jonathan Jansen’s prestige scholars have become sought after in the academic community at large, as this recent appointment at the University of Kent indicates,” says Professor Neil Roos, co-director of the PSP. “Yet the alumni’s commitment to the programme, the university and their peers continues.”

Cohen is the editor (with Casper Andersen) of the five volume, The Government and Administration of Africa, 1880-1939. Dr Cohen’s next project is forthcoming from I.B. Tauris, The Politics and Economics of Decolonisation: The Failed Experiment of the Central African Federation.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept